Saudi Aramco To Maintain Oil Deliveries To Asian Clients Despite OPEC+ Cuts – VanEck Russia ETF (BATS:RSX), SPDR Gold Trust (ARCA:GLD)
[ad_1] Saudi Aramco said it would maintain contract oil volumes to clients in Asia despite the recently agreed OPEC+ production cuts, despite the Organization of the Petroleum Exporting Countries…
HC Wainwright Initiates Aptorum On Upcoming “Innovative Pipeline” – Aptorum Gr (NASDAQ:APM)
[ad_1] HC Wainwright initiated coverage on Aptorum Group Limited APM with a Buy rating and a price target of $8. The analyst is bullish on Aptorum based on three points: Promising…
Why PureTech Health (PRTC) Shares Are Plunging Today – Nektar Therapeutics (NASDAQ:NKTR)
[ad_1] PureTech Health plc PRTC has confirmed that it is in talks about a possible tie-up with Nektar Therapeutics NKTR. In April, Nektar Therapeutics announced a new strategic plan to prioritize key research…
Alnylam’s Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease – Alnylam Pharmaceuticals (NASDAQ:ALNY)
[ad_1] The FDA approved a label expansion for Alnylam Pharmaceuticals Inc’s ALNY for Oxlumo (lumasiran), an RNAi therapeutic administered via subcutaneous injection, now indicated for the treatment of primary hyperoxaluria type 1 (PH1)…
Walmart To Let Go More Than 1,000 Employees At Atlanta Fulfillment Center – Walmart (NYSE:WMT)
[ad_1] As per a Worker Adjustment and Retraining Notification, Walmart Inc WMT looks to lay off 1,458 workers at the e-commerce fulfillment center in Fulton Parkway in Atlanta, Georgia. “We’re…
Verve’s Stock Price Could Continue To Rise Through Clinical Progress – Despite Worries About “DeeperPocketed” Competition – Verve Therapeutics (NASDAQ:VERV)
[ad_1] Credit Suisse has initiated coverage on Verve Therapeutics Inc VERV with a Neutral rating and a $48 target price. Its lead assets are VERVE-101 for heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic…
Stephen Initiates This Spatial Biology Player Citing Strong Competitive Position – Akoya Biosciences (NASDAQ:AKYA)
[ad_1] Stephens started coverage on Akoya Biosciences Inc AKYA with an Overweight rating and price target of $16. The analyst views Akoya as a leader in the rapidly advancing $14 billion…
Analyst Initiates Coverage On This Genetic Testing Stock With Ongoing Transformation – Myriad Genetics (NASDAQ:MYGN)
[ad_1] Stephens initiated coverage on Myriad Genetics Inc MYGN with an Equal-Weight rating and a price target of $22. The analyst writes that the company has been at the forefront of genetic…
Aldeyra’s ADX-2191 Aces Late-Stage Study In Rare Vision Disorder – Aldeyra Therapeutics (NASDAQ:ALDX)
[ad_1] Aldeyra Therapeutics Inc ALDX achieved the primary endpoint in Part 1 of the Phase 3 GUARD Trial of ADX-2191 (methotrexate injection, USP) for intravitreal administration to prevent proliferative vitreoretinopathy (PVR). …
Applied Therapeutics’ Lead Candidate Pediatric Study Failed To Reach Statistical Significance – Applied Therapeutics (NASDAQ:APLT)
[ad_1] Applied Therapeutics Inc’s APLT ACTION-Galactosemia Kids Phase 3 trial has demonstrated a trend in clinical benefit favoring AT-007 vs. placebo. The study is designed to evaluate the impact…
Tesla To Feel Pressure After Musk’s Twitter-Deal News; OPEC Output Cut Disappoints Biden; Shell Profits Low: Top Stories Thursday, Oct. 6 – American Airlines Group (NASDAQ:AAL), Amazon.com (NASDAQ:AMZN)
[ad_1] Benzinga Tesla Shares Will Remain Under Pressure After Twitter-Deal News, Analyst Says — Unless Elon Musk Gives Clarity Elon Musk on Tuesday renewed his interest in Twitter Inc. TWTR for…
Siemens Energy Unclear On Spanish Regulator Nod For Siemens Gamesa Takeover – Siemens Energy (OTC:SMNEY)
[ad_1] Siemens Energy AG SMNEY SMEGF is reportedly in talks with Spain’s stock market supervisor on a planned takeover bid for the struggling wind turbine maker Siemens Gamesa but is…
WHO Says India-Made Cough Syrups May Be Linked To 66 Deaths In Gambia: Report
[ad_1] The dozens of kids’ death in Gambia due to kidney injuries may have links to contaminated cough and cold syrups made by an Indian drug manufacturer. In…
HC Wainwright Initiates This Eye-Focused Stock With Almost 400% Upside – Eyenovia (NASDAQ:EYEN)
[ad_1] HC Wainwright Matthew Caufield initiated coverage on Eyenovia Inc EYEN, focused on developing ophthalmic therapeutics based on the company’s microdose array print (MAP) platform and the Optejet spray device for optimizing…
Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study – Eliem Therapeutics (NASDAQ:ELYM)
[ad_1] Eliem Therapeutics Inc ELYM announced interim results from its ongoing Phase 1 trial of ETX-155 for major depressive disorder (MDD) and epilepsy. Following lower-than-expected drug exposure levels in the three…
Elon Musk Renews Twitter’s Buyout Proposal, Apple Suppliers Working On Cutting China Reliance, E-Cigarette Maker Considers Bankruptcy: Top Stories Wednesday, Oct. 5 – Apple (NASDAQ:AAPL), Amazon.com (NASDAQ:AMZN)
[ad_1] Wall Street Journal Apple Suppliers Slowly Boosting US Presence To Cut China Reliance Apple Inc suppliers are gradually establishing new production facilities in the U.S., focusing on California, to…
Russian Gas Firm Gazprom Resumes Gas Deliveries To Italy Via Austria – Eni (NYSE:E)
[ad_1] Russian gas giant Gazprom is resuming transportation of Russian gas to Italy via Austria, saying a necessary solution was reached with the Italian buyers for the gas flow. “The…
Sight Sciences’ Near-Term Upside Is Limited, Says This Analyst – Sight Sciences (NASDAQ:SGHT)
[ad_1] Needham initiated coverage on Sight Sciences Inc SGHT with a Hold rating and no price target. The analyst warns that the recent competitive launches in the minimally invasive glaucoma surgery (MIGS) market…
Adamis Pharmaceuticals Seeks Strategic Options, Including Sale – Adamis Pharmaceuticals (NASDAQ:ADMP)
[ad_1] Adamis Pharmaceuticals Corp ADMP has initiated a process to explore a range of strategic and financing alternatives. The move follows the recently announced halting of the company’s Phase 2/3 trial examining the…
Biohaven’s ALS Drug Fails To Meet Study Endpoint, Second Therapy To Fail Trials In Recent Months – Biohaven Pharma Hldgs (NYSE:BHVN)
[ad_1] Biohaven Pharmaceutical Holding Company Ltd BHVN announced results from a focused analysis of verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS). Verdiperstat did not statistically…
Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study – Alzamend Neuro (NASDAQ:ALZN)
[ad_1] Alzamend Neuro Inc ALZN submitted an investigational new drug application to the FDA for its immunotherapy candidate, ALZN002. The product candidate is designed to treat mild to moderate dementia of…
Vietnam Law May Impact Facebook, Twitter; Amazon Has A Sleep Tracker; India Lures Apple, Dell, HP: Top Financial Media Stories Thursday, Sept. 29 – Apple (NASDAQ:AAPL), Amazon.com (NASDAQ:AMZN)
[ad_1] Reuters Vietnam’s Social Media Law May Impact Facebook, YouTube, Twitter Vietnam plans to introduce new laws to limit which social media accounts can post news-related content. This could…
Axcella Shares Jump Despite Mixed Bag Data From Mid-Stage NASH Trial – Axcella Health (NASDAQ:AXLA)
[ad_1] Axcella Therapeutics AXLA reported interim results from its ongoing global Phase 2b EMMPACT study of AXA1125 for nonalcoholic steatohepatitis (NASH). At 24 weeks, Axcella said all patients taking the high…
These Stocks Are On The Radar After Biogen-Eisai’s Surprising Alzheimer’s Trial Win – Biogen (NASDAQ:BIIB)
[ad_1] One of the most-watched Alzheimer’s therapies in the clinic, Biogen Inc BIIB–Eisai Limited’s ESALY experimental lecanemab reduced clinical decline on the scale by 27% compared to the placebo at 18 months…
OraSure Secures BARDA Funding For Next-Gen Ebola Diagnostic Test – OraSure Technologies (NASDAQ:OSUR)
[ad_1] The Biomedical Advanced Research and Development Authority (BARDA) has issued an $8.6 million contract to OraSure Technologies Inc OSUR for developing a 2nd generation Ebola test on the OraQuick testing platform. …